Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar. Closed at $7.20, 41% below $12.19, its close on the day of its Sep 24 private placement. Of biotech stocks this far below their close on the day of a recent offering, 76% were lower 60 trading days later (median -29%). How we know
$12,052Cash on Hand
0.3mo Cash Runway
Follow BKHA by emailGet an email when BKHA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BKHA, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Oct 23, 2026 ·
Shareholder vote Black Hawk Acquisition Corp deposited an aggregate of $150,000 into its trust account on October 22, 2026, extending its deadline to complete an initial business combination by one month, from October 22, 2026 to November 22, 2026. Form 8-K · SEC filing
Oct 13, 2026 ·
Shareholder vote Shareholders of Black Hawk Acquisition approved all eight proposals at an October 13, 2026 extraordinary meeting, including the business combination with Vesicor Therapeutics and the domestication to Delaware. Holders of 2,089,162 shares redeemed for $25,153,510.48, about $12.04 per share. Form 8-K · SEC filing
Oct 6, 2026 ·
Quarterly report for the period ended Aug 31, 2026 Form 10-Q · SEC filing
Sep 24, 2026 ·
Financing Black Hawk Acquisition agreed with Meteora on a forward purchase of up to 1,350,000 shares at an initial price equal to the trust redemption price, with a $10.00 reset price and a 36-month valuation date. Form 8-K · SEC filing
Sep 22, 2026 ·
Shareholder vote Black Hawk Acquisition shareholders will vote on a business combination with Vesicor Therapeutics at an October 13, 2026 extraordinary general meeting, with an Equity Value of $70,000,000. About $22.7 million remains in the trust after 69.2% of public shares were redeemed. Form 424B4 · SEC filing
Sep 22, 2026 ·
An aggregate of $150,000 was deposited into the trust account for public shareholders, extending the period to complete an initial business combination by one month, from September 22, 2026 to October 22, 2026. Form 8-K · SEC filing
Aug 26, 2026 ·
Financing Black Hawk Management LLC, the sponsor, lent up to $300,000 via a convertible note bearing 10% interest. Principal is due at a DeSPAC closing or liquidation, and convertible at $1.00 per share. Form 8-K · SEC filing
Aug 25, 2026 ·
Black Hawk Acquisition deposited $150,000 into its trust account for public shareholders, extending the deadline to complete its initial business combination by one month, from August 22, 2026 to September 22, 2026. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jan 2027 · N/A · Upcoming Trial · Black Forest Cocoa Flavanol Supplementation and Health Trial Registry primary completion date, not a results date
Nov 2028 · Phase 2 · Recruiting · Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII Registry primary completion date, not a results date
Jun 2030 · Phase 1/2 · Enrolling · Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF… Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not BKHA's own candidates): Temozolomide, Azathioprine, Carfilzomib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
BKHA holds $12,052 in cash and short-term investments and burns about $140,017/quarter from operations,
an estimated runway of 0.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:45 · Elevated
Cash runway 0 months +40
Going-concern doubt in the latest 10-Q +15In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that these conditions…10-Q, Oct 2026
Raised after last reported balance sheet (Sep 2026) -10
Share count 4,153,577 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full BKHA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BKHA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.